Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
protoporphyrin IX-beta-cyclodextrin conjugate
- Development stage
- Preclinical
- Modality
- Biodegradable Polymers → Polymer-based Nanoparticles → Nanoparticles → Drug Delivery Systems
- Administration
- Topical, Intravenous
01
Overview
Protoporphyrin IX-beta-cyclodextrin conjugate is a covalent polymer-drug conjugate developed for multimodal cancer therapy and imaging. It consists of the photosensitizer protoporphyrin IX (PpIX) covalently linked at both carboxylic termini to the drug carrier beta-cyclodextrin (betaCD). This modification enhances the water solubility of PpIX and promotes its preferential localization within the mitochondria of malignant cells, such as MCF7 breast cancer and DU145 prostate cancer lines. Upon light activation, the PpIX moiety generates reactive oxygen species for photodynamic therapy (PDT), while its inherent fluorescence allows for diagnostic imaging. Furthermore, the cyclodextrin component can encapsulate hydrophobic drugs like N-desmethyltamoxifen, enabling a synergistic combination of phototoxicity and adjuvant chemotherapy.
- Other names
- PpIX-beta-cyclodextrinPpIX+betaCDPpIX-betaCD conjugate
Beyond the preview
Go deeper on protoporphyrin IX-beta-cyclodextrin conjugate.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on protoporphyrin IX-beta-cyclodextrin conjugate.